Cardiac complications of chronic obstructive pulmonary disease

Czech version

Authors: J. Chlumský ¹; J. Chlumský ²
Authors‘ workplace: Univerzita Karlova v Praze 2. lékařská fakulta a Fakultní nemocnice Motol ; Interní klinika Přednosta: prof. MUDr. Milan Kvapil, CSc., MBA 1. lékařská fakulta a Fakultní Thomayerova nemocnice ¹; Pneumologická klinika Přednosta: prof. MUDr. Jiří Homolka, DrSc. ²
Published in: Prakt. Lék. 2010; 90(2): 82-85
Category: Various Specialization

Overview

Cardiovascular diseases and cancer are the two leading causes of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD). In patients with mild COPD, cardiovascular diseases account for nearly 50 % of all hospitalizations and over 20 % of all deaths. COPD doubles the risk of cardiovascular disease and lung cancer. The spectrum of cardiovascular diseases includes

– right ventricular dysfunction,

– pulmonary hypertension,

– coronary artery disease, and

– arrhythmias.

Pulmonary hypertension associated with COPD increases morbidity and worsens survival. Patients with COPD also carry an increased risk of mortality due to arrhythmia, myocardial infarction or congestive heart failure. The general approach to treating cardiovascular disease in COPD is similar to that used in the general population.

Key words:
pulmonary hypertension, cor pulmonale, coronary artery disease.

Sources

1. Arcasoy, S.M., Christie, J.D., Ferrari, V.A. et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am. J. Respir. Crit. Care Med. 2003, 167, p. 735–740.

2. Au, D.H., Bryson, C.L., Fan, V.S. et al. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am. J. Med. 2004, 117, p. 925-931.

3. Curkendall, S.M., Lanes, S., de Luise, C. et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur. J. Epidemiol. 2006, 21, p. 803–813.

4. Curkendall, S.M., Deluise, C., Jones, J.K. et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann. Epidemiol. 2006, 16, p. 63–70.

5. Dahl, M., Vestbo, J., Lange, P. et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007, 175, p. 250-255.

6. Engstrom, G., Wollmer, P., Hedblad, B. et al. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from ‘men born in 1914, Malmo, Sweden. Circulation 2001, 103, p. 3086-3091.

7. Engstrom, G., Hedblad, B., Janzon, L., Valind, S. Respiratory decline in smokers and ex-smokers-an independent risk factor for cardiovascular disease and death. J. Cardiovasc. Risk 2000, 7, p. 267-272.

8. Fisher, M.R., Criner, G.J., Fishman, A.P. et al. Estimating pulmonary artery pressure by echocardiography in patients with emphysema. Eur. Respir. J. 2007, 30, p. 914–921.

9. Gan, W.Q., Man ,S.F., Senthilselvan, A., Sin, D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59, p. 574-580.

10. Hunninghake, D. Cardiovascular disease in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005, 2, p. 44–49.

11. Chaouat, A., Bugnet, A., Kadaoui, N. et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005, 172, p. 189-194.

12. Chlumský, J. Tolerance fyzické zátěže u pacientů s chronickou obstrukční plicní nemocí. Čas. Lék. Čes. 2005, 6, s. 372-376.

13. Chlumský, J., Charvát, J. Plicní embolie. Prakt. lék. 2007, 87, s. 456-460.

14. Le Jemtel, T.H., Padeletti, M., Jelic, S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J. Am. Coll. Cardiol. 2007, 49, p. 171–180.

15. Leuchte, H.H., Baumgartner, R.A., Nounou, M.E. et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am. J. Respir. Crit. Care Med. 2006, 173, p. 744-750.

16. Man, S.F., Connett, J.E., Anthonisen, N.R. et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006, 61, p. 849-853.

17. Mancini, G.B., Etminan, M., Zhang, B. et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 2006, 47, p. 2554-2560.

18. McGarvey, L.P., John, M., Anderson, J.A. et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007, 62, p. 411-415.

19. Murray, C.J., Lopez, A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997, 349, p. 1436-1442.

20. Oswald-Mammosser, M., Weitzenblum, E., Quoix, E. et al. Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 1995, 107, p. 1193–1198.

21. Rabe, K.F., Hurd, S., Anzueto, A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am, J. Respir. Crit. Care Med. 2007, 176, p. 532-555.

22. Ross, R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340, p. 115-126.

23. Sidney, S., Sorel, M., Quesenberry, C.P. et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005, 128, p. 2068-2075.

24. Sin, D.D., Man, S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107, p. 1514-1519.

25. Sin, D.D., Wu, L., Man, S.F. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005, 127, p. 1952-1959.

26. Soyseth, V., Brekke, P.H., Smith, P. Omland, T. Statin use is associated with reduced mortality in COPD. Eur. Respir. J. 2007, 29, p. 279-283.

27. van der Woude, H.J., Zaagsma, J., Postma, D.S. et al. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest 2005, 127, p. 818-824.

28. Widimský, J. Plicní hypertenze u chronické obstrukční plicní nemoci. Cor Vasa 2009, 51, 462-469.